Literature DB >> 19698411

Withdrawal from benzodiazepines by initially switching to zopiclone.

C Shapiro1, D Sherman, D Peck.   

Abstract

Withdrawal from hypnotics can produce a variety of problems, especially sleep difficulties, some of which may arise from the multiple actions of most hypnotics, thus producing a range of rebound effects. This study examined whether switching patients to a hypnotic with a narrower range of action and of a different class would reduce these problems. One hundred and thirty-four patients participated; they were randomly allocated to one of three methods of switching from "previous hypnotic" to zopiclone (a cyclopyrrolone). The methods were gap (an interval between taking the two drugs); abuttal (taking zopiclone immediately on stopping previous drug); and overlap (gradually reducing previous drug after starting zopiclone). The main findings were that zopiclone was associated with better sleep and increased alertness; the abuttal method was the best method of switching; and no serious side effects from zopiclone were reported. It was concluded that zopiclone has a useful role in benzodiazepine withdrawal, and that immediate substitution is the best method.

Entities:  

Year:  1995        PMID: 19698411     DOI: 10.1016/0924-9338(96)80096-4

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  8 in total

1.  Treatment of primary insomnia.

Authors:  J Montplaisir
Journal:  CMAJ       Date:  2000-08-22       Impact factor: 8.262

2. 

Authors:  Kevin Pottie; Wade Thompson; Simon Davies; Jean Grenier; Cheryl A Sadowski; Vivian Welch; Anne Holbrook; Cynthia Boyd; Robert Swenson; Andy Ma; Barbara Farrell
Journal:  Can Fam Physician       Date:  2018-05       Impact factor: 3.275

Review 3.  Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia.

Authors:  S Noble; H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

4.  Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.

Authors:  Kevin Pottie; Wade Thompson; Simon Davies; Jean Grenier; Cheryl A Sadowski; Vivian Welch; Anne Holbrook; Cynthia Boyd; Robert Swenson; Andy Ma; Barbara Farrell
Journal:  Can Fam Physician       Date:  2018-05       Impact factor: 3.275

5.  Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial.

Authors:  Lucie Baillargeon; Philippe Landreville; René Verreault; Jean-Pierre Beauchemin; Jean-Pierre Grégoire; Charles M Morin
Journal:  CMAJ       Date:  2003-11-11       Impact factor: 8.262

6.  An approach to long-term sedative-hypnotic use.

Authors:  Azmeh Shahid; Sharon A Chung; Ron Phillipson; Colin M Shapiro
Journal:  Nat Sci Sleep       Date:  2012-04-02

Review 7.  Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review.

Authors:  André S Pollmann; Andrea L Murphy; Joel C Bergman; David M Gardner
Journal:  BMC Pharmacol Toxicol       Date:  2015-07-04       Impact factor: 2.483

Review 8.  Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users.

Authors:  Lone Baandrup; Bjørn H Ebdrup; Jesper Ø Rasmussen; Jane Lindschou; Christian Gluud; Birte Y Glenthøj
Journal:  Cochrane Database Syst Rev       Date:  2018-03-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.